Skip to main content
Erschienen in:

10.01.2022 | Research Article

Analysis of related factors of cervical intraepithelial neoplasia complicated with vaginal intraepithelial neoplasia

verfasst von: Y.Y. Zhang, R. Xia, D. Chen, X. Zhang

Erschienen in: Clinical and Translational Oncology | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To explore the underlying risk factors and to prevent misdiagnosis of cervical intraepithelial neoplasia (CIN) coexisted with vaginal intraepithelial neoplasia (VaIN).

Methods

Clinical data of patients pathologically diagnosed with CIN were collected from January 2017 to December 2018. A total of 446 cases were analyzed, including 406 cases of single lesions (‘CIN single’ group) and 40 cases complicated with VAIN (‘VAIN concurrent’ group).

Results

The median age of the VAIN concurrent group was 53 years (46.25–59 years), and the median age of the CIN single group was 44 years (36–50 years). Regarding menopausal status, there were 28 cases (70.0%) in the VAIN concurrent group and 89 cases (21.9%) in the CIN single group (P < 0.005). The median load of high-risk human papillomavirus (Hr-HPV) in the VAIN concurrent and CIN single group was 923.4 relative light units/cutoff (RLU/CO) (145–2172.2 RLU/CO) and 229.155 RLU/CO (18.615–638.1275 RLU/CO), respectively (P = 0.037). The results revealed that the menopausal status was an independent risk factor for VAIN occurrence in CIN patients. The risk of VAIN in menopausal patients was higher than that in non-menopausal CIN patients (OR = 8.311, 95% CI 4.062–17.005). Age and HPV load were also related to the concurrence of VAIN and CIN.

Conclusion

Examinations regarding vaginal screening are of great importance in the diagnosis of perimenopausal and postmenopausal CIN patients, especially patients with Hr-HPV load. Colposcopy and tissue biopsy should also be performed, when necessary, to avoid misdiagnosis and the appearance of vaginal lesions.
Literatur
1.
Zurück zum Zitat Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013;17:S1–27.CrossRefPubMed Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013;17:S1–27.CrossRefPubMed
2.
Zurück zum Zitat Siegler E, Segev Y, Mackuli L, Auslender R, Shiner M, Lavie O. Vulvar and vaginal cancer, vulvar intraepithelial neoplasia 3 and vaginal intraepithelial neoplasia 3: experience of a referral institute. Isr Med Assoc J. 2016;18:286–9.PubMed Siegler E, Segev Y, Mackuli L, Auslender R, Shiner M, Lavie O. Vulvar and vaginal cancer, vulvar intraepithelial neoplasia 3 and vaginal intraepithelial neoplasia 3: experience of a referral institute. Isr Med Assoc J. 2016;18:286–9.PubMed
3.
Zurück zum Zitat Murta EF, Neves Junior MA, Sempionato LR, Costa MC, Maluf PJ. Vaginal intraepithelial neoplasia: clinical-therapeutic analysis of 33 cases. Arch Gynecol Obstet. 2005;272:261–4.CrossRefPubMed Murta EF, Neves Junior MA, Sempionato LR, Costa MC, Maluf PJ. Vaginal intraepithelial neoplasia: clinical-therapeutic analysis of 33 cases. Arch Gynecol Obstet. 2005;272:261–4.CrossRefPubMed
4.
Zurück zum Zitat Gunderson CC, Nugent EK, Elfrink SH, Gold MA, Moore KN. A contemporary analysis of epidemiology and management of vaginal intraepithelial neoplasia. Am J Obstet Gynecol. 2013;208:410.e1-410.e6.CrossRef Gunderson CC, Nugent EK, Elfrink SH, Gold MA, Moore KN. A contemporary analysis of epidemiology and management of vaginal intraepithelial neoplasia. Am J Obstet Gynecol. 2013;208:410.e1-410.e6.CrossRef
5.
Zurück zum Zitat Wee WW, Chia YN, Yam PKL. Diagnosis and treatment of vaginal intraepithelial neoplasia. BJOG. 2012;117:15–7. Wee WW, Chia YN, Yam PKL. Diagnosis and treatment of vaginal intraepithelial neoplasia. BJOG. 2012;117:15–7.
6.
Zurück zum Zitat Bo C, Lan Z. Clinical analysis of 28 cases of vaginal intraepithelial neoplasia. Chin J Pract Gynecol Obstet 2012;918–20. Bo C, Lan Z. Clinical analysis of 28 cases of vaginal intraepithelial neoplasia. Chin J Pract Gynecol Obstet 2012;918–20.
7.
Zurück zum Zitat Zhao HP, Xue QS, Yu BW, et al. Clinical analysis of 56 cases with vaginal intraepithelial neoplasia after hysterectomy. J Shanghai Jiaotong Univ (Medical Science). 2017;37:661–5. Zhao HP, Xue QS, Yu BW, et al. Clinical analysis of 56 cases with vaginal intraepithelial neoplasia after hysterectomy. J Shanghai Jiaotong Univ (Medical Science). 2017;37:661–5.
8.
Zurück zum Zitat He Y, Zhao Q, Geng YN, Yang SL, Yin CH, Wu YM. Clinical analysis of cervical intraepithelial neoplasia with vaginal intraepithelial neoplasia. Medicine. 2017;96: e6700.CrossRefPubMedPubMedCentral He Y, Zhao Q, Geng YN, Yang SL, Yin CH, Wu YM. Clinical analysis of cervical intraepithelial neoplasia with vaginal intraepithelial neoplasia. Medicine. 2017;96: e6700.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Frega A, Sopracordevole F, Assorgi C, Lombardi D, Sanctis DEV, Catalano A, et al. Vaginal intraepithelial neoplasia: a therapeutical dilemma. Anticancer Res. 2013;33:29–38.PubMed Frega A, Sopracordevole F, Assorgi C, Lombardi D, Sanctis DEV, Catalano A, et al. Vaginal intraepithelial neoplasia: a therapeutical dilemma. Anticancer Res. 2013;33:29–38.PubMed
10.
Zurück zum Zitat Song JH, Lee JH, Lee JH, Park JS, Hong SH, Jang HS, et al. High-dose-rate brachytherapy for the treatment of vaginal intraepithelial neoplasia. Cancer Res Treat. 2014;46:74–80.CrossRefPubMedPubMedCentral Song JH, Lee JH, Lee JH, Park JS, Hong SH, Jang HS, et al. High-dose-rate brachytherapy for the treatment of vaginal intraepithelial neoplasia. Cancer Res Treat. 2014;46:74–80.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Kurman RJ, Carcangiu ML, Herrington CS, et al. WHO classification of tumours of female reproductive organs. 4th ed. Lyon: IARC Press; 2014. p. 228–53. Kurman RJ, Carcangiu ML, Herrington CS, et al. WHO classification of tumours of female reproductive organs. 4th ed. Lyon: IARC Press; 2014. p. 228–53.
12.
Zurück zum Zitat Lamos C, Mihaljevic C, Aulmann S, Bruckner T, Domschke C, Wallwiener M, et al. Detection of human papillomavirus infection in patients with vaginal intraepithelial neoplasia. PLoS ONE. 2016;11: e0167386.CrossRefPubMedPubMedCentral Lamos C, Mihaljevic C, Aulmann S, Bruckner T, Domschke C, Wallwiener M, et al. Detection of human papillomavirus infection in patients with vaginal intraepithelial neoplasia. PLoS ONE. 2016;11: e0167386.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114–9.CrossRefPubMed Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114–9.CrossRefPubMed
14.
Zurück zum Zitat Liu Q, Ding H, Wu YL, et al. 88 Cases of clinical analysis of vaginal intraepithelial neoplasia after hysterectomy of cervical cancer and high-grade cervical intraepithelial neoplasia. J Pract Obstet and Gynecol. 2017;33:438–42. Liu Q, Ding H, Wu YL, et al. 88 Cases of clinical analysis of vaginal intraepithelial neoplasia after hysterectomy of cervical cancer and high-grade cervical intraepithelial neoplasia. J Pract Obstet and Gynecol. 2017;33:438–42.
15.
Zurück zum Zitat Audet-Lapointe P, Body G, Vauclair R, Drouin P, Ayoub J. Vaginal intraepithelial neoplasia. Gynecol Oncol. 1990;36:232–9.CrossRefPubMed Audet-Lapointe P, Body G, Vauclair R, Drouin P, Ayoub J. Vaginal intraepithelial neoplasia. Gynecol Oncol. 1990;36:232–9.CrossRefPubMed
16.
Zurück zum Zitat Chao A, Chen TC, Hsueh C, et al. Human papillomavirus in vaginal intraepithelial neoplasia. Int J Cancer Epub. 2012;131:E259-268.CrossRef Chao A, Chen TC, Hsueh C, et al. Human papillomavirus in vaginal intraepithelial neoplasia. Int J Cancer Epub. 2012;131:E259-268.CrossRef
17.
Zurück zum Zitat Li H, Guo YL, Zhang JX, Qiao J, Geng L. Risk factors for the development of vaginal intraepithelial neoplasia. Chin Med J (Engl). 2012;125:1219–23. Li H, Guo YL, Zhang JX, Qiao J, Geng L. Risk factors for the development of vaginal intraepithelial neoplasia. Chin Med J (Engl). 2012;125:1219–23.
18.
Zurück zum Zitat Hui Y, Manna P, Ou JJ, Kerley S, Zhang C, Sung CJ, et al. High-risk human papillomavirus infection involving multiple anatomic sites of the female lower genital tract: a multiplex real-time polymerase chain reaction-based study. Hum Pathol. 2015;46:1376–81.CrossRefPubMed Hui Y, Manna P, Ou JJ, Kerley S, Zhang C, Sung CJ, et al. High-risk human papillomavirus infection involving multiple anatomic sites of the female lower genital tract: a multiplex real-time polymerase chain reaction-based study. Hum Pathol. 2015;46:1376–81.CrossRefPubMed
19.
Zurück zum Zitat Park JY, Lee KH, Dong SM, Kang S, Park SY, Seo SS. The association of pre-conization high-risk HPV load and the persistence of HPV infection and persistence/recurrence of cervical intraepithelial neoplasia after conization. Gynecol Oncol. 2008;108:549–54.CrossRefPubMed Park JY, Lee KH, Dong SM, Kang S, Park SY, Seo SS. The association of pre-conization high-risk HPV load and the persistence of HPV infection and persistence/recurrence of cervical intraepithelial neoplasia after conization. Gynecol Oncol. 2008;108:549–54.CrossRefPubMed
20.
Zurück zum Zitat Bogani G, Martinelli F, Ditto A, Taverna F, Lombardo C, Signorelli M, et al. Human papillomavirus (HPV) persistence and HPV 31 predict the risk of recurrence in high-grade vaginal intraepithelial neoplasia. Eur J Obstet Gynecol Reprod Biol. 2017;210:157–65.CrossRefPubMed Bogani G, Martinelli F, Ditto A, Taverna F, Lombardo C, Signorelli M, et al. Human papillomavirus (HPV) persistence and HPV 31 predict the risk of recurrence in high-grade vaginal intraepithelial neoplasia. Eur J Obstet Gynecol Reprod Biol. 2017;210:157–65.CrossRefPubMed
21.
Zurück zum Zitat Dodge JA, Eltabbakh GH, Mount SL, Walker RR, Morgan A. Clinical features and risk of recurrence among patients with vaginal intraepithelial neoplasia. Gynecol Oncol. 2001;83:363–9.CrossRefPubMed Dodge JA, Eltabbakh GH, Mount SL, Walker RR, Morgan A. Clinical features and risk of recurrence among patients with vaginal intraepithelial neoplasia. Gynecol Oncol. 2001;83:363–9.CrossRefPubMed
22.
Zurück zum Zitat Karoliina T, Maija J, Karolina L, Kalliala I, Paavonen J, Nieminen P, et al. Randomised trial on treatment of vaginal intraepithelial neoplasia-Imiquimod, laser vaporisation and expectant management. Int J Cancer. 2016;139:2353–8.CrossRef Karoliina T, Maija J, Karolina L, Kalliala I, Paavonen J, Nieminen P, et al. Randomised trial on treatment of vaginal intraepithelial neoplasia-Imiquimod, laser vaporisation and expectant management. Int J Cancer. 2016;139:2353–8.CrossRef
Metadaten
Titel
Analysis of related factors of cervical intraepithelial neoplasia complicated with vaginal intraepithelial neoplasia
verfasst von
Y.Y. Zhang
R. Xia
D. Chen
X. Zhang
Publikationsdatum
10.01.2022
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 5/2022
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-021-02739-x

Neu im Fachgebiet Onkologie

Nierenzellkarzinom: Kein Nachteil durch subkutan appliziertes Nivolumab

Die subkutane Applikation von Nivolumab ist nach Daten einer Phase-3-Studie ähnlich gut wirksam wie die intravenöse: Die Pharmakokinetik ist vergleichbar, die objektive Response war in der Studie sogar leicht besser als in der Gruppe mit Infusionen.

Vorteile für Androgenentzug plus Androgenrezeptorblockade

Für Männer mit metastasiertem hormonsensitivem Prostata-Ca. (mHSPC), die keine Hormonchemotherapie wollen oder vertragen, ist der Androgenentzug plus Darolutamid eine Alternative: Das Progressionsrisiko wird im Vergleich zum alleinigen Androgenentzug fast halbiert.

CDK4/6-Inhibitoren bei Brustkrebs in die Zweitlinie aufschieben?

Ergebnisse einer Phase-III-Studie sprechen dafür, dass die Behandlung mit CDK4/6-Inhibitoren bei fortgeschrittenem HR-positivem, HER2-negativem Brustkrebs auch auf die Zweitlinie verschoben werden könnte, ohne die onkologischen Ergebnisse zu kompromittieren.

Cannabisextrakt verbessert Antiemese bei Chemotherapie

Sprechen Krebskranke auf die übliche Antiemese während einer Chemotherapie nicht ausreichend an, lohnt sich möglicherweise eine Behandlung mit Cannabisextrakt. In einer Phase-2/3-Studie ließ sich die antiemetische Response mit einem solchen Extrakt erheblich verbessern.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.